NCCN 2019 Annual Congress: Hematologic Malignancies™


Saturday, September 28

Lunch Symposium: 12:10 - 1:10 PM 

Approaches to Individualized Treatment for Chronic Lymphocytic Leukemia:
Expert Guidance on Sequencing Therapy, Novel Agents, and their Combinations


​Presented by:
Jeremy S. Abramson, MD, MMSc, Massachusetts General Hospital Cancer Center
William G. Wierda, MD, PhD, The University of Texas MD Anderson Cancer Center

This symposium will present a unique opportunity for the interprofessional cancer care team to learn about individualized treatment for chronic lymphocytic leukemia (CLL). This case-based, expert-led educational program will feature presentations including patient case studies and key clinical trial data with renowned clinical experts providing their perspectives on recent changes and the rationale for the development of novel treatment options that are improving patient care.

Provided by NCCN in partnership with Clinical Care Options, LLC

This session is open to all health care providers attending the congress; pre-registration is not required. CME/CNE/CPE available. This symposium is accredited and supported separately from all other educational sessions on the general session agenda. Seating is limited and on a first-come, first-seated basis.

Learning Objectives: Upon completion of this activity, participants should be able to:

  • Consider the efficacy and safety profile of the therapeutic agent along with patient characteristics and molecular features of CLL to individualize therapeutic strategies for newly diagnosed CLL.
  • Choose optimal treatment for relapsed/refractory CLL based on the available clinical data, guidelines, and expert recommendations.
  • Plan treatment strategies that sequence targeted agents to optimize patient outcomes and quality of life.
  • Evaluate the efficacy, toxicity profile and other practical management considerations assocaited with novel approved and investigational agents and combination regimens in CLL.
  • Manage adverse events associated with treatment approaches for CLL to ensure treatment compliance to improve clinical outcomes and quality of life.

Supporters:
This activity is supported by an educational grant from AstraZeneca.
This activity is supported by an independent medical education grant from Pharmacyclics LLC and Janssen.

Outlook Outlook
iCal iCal
Google Google
Yahoo! Yahoo!
MSN MSN
Top